Ashland reports financial results1 for fourth-quarter fiscal

Sales of $518 million, down eighteen percent from the prior-year quarterNet loss of $4 million, or $0.07 per diluted shareLoss from continuing operations of $8 million, or $0.15 per diluted...

Related Keywords

Ukraine , Russia , Setha Mrozek , Guillermo Novo , Carolmariec Brown , Life Sciences , Ashland Inc , Securities Exchange , Exchange Commission , Us Accounts Receivable Sales Program , Performance Adhesives , Innovation Day , Investor Relations , Securities Act , Securities Exchange Act , Risk Factors , Receivable Sales Program , Markets ,